Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Rhabdomyosarcoma 5Prostatic Neoplasms 5Sarcoma, Synovial 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Sarcoma, Ewing 2Neoplasm Metastasis 2Lung Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Head and Neck Neoplasms 2Fibrosarcoma 2Colorectal Neoplasms 2Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Uveal Melanoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Retinoblastoma 1Rectal Neoplasms 1Pinealoma 1

Interventions

Cisplatin 116Radiotherapy 84Paclitaxel 77Fluorouracil 62Carboplatin 41Drug Therapy 38pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26Neoadjuvant Therapy 24Oxaliplatin 23toripalimab 22sintilimab 19camrelizumab 19Radiation 19Esophagectomy 18Capecitabine 17130-nm albumin-bound paclitaxel 17Surgical Procedures, Operative 16Nivolumab 16Leucovorin 15Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10Immune Checkpoint Inhibitors 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × cixutumumab × Clear all
NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡